检索结果-内蒙古大学图书馆

Comparison of clinical and pathological staging and long-term results of liver transplantation for hepatocellular carcinoma in a single transplant center

引用

TRANSPLANTATION PROCEEDINGS 2006年第4期38卷 1111-1113页

作者： Baccarani, U. Adani, G. L. Avellini, C. Lorenzin, D. Curro, G. Beltrami, A. Pasqualucci, A. Bresadola, V. Risaliti, A. Viale, P. L. Beltrami, C. A. Bresadola, F. Univ Udine Dept Surg I-33100 Udine Italy Univ Udine Transplantat Unit I-33100 Udine Italy Univ Hosp Udine Inst Infect Dis Udine Italy Univ Hosp Udine Inst Pathol Udine Italy

Liver transplantation (OLT) is a treatment for hepatocellular carcinoma (HCC) superimposed on cirrhosis provided that the disease meets defined criteria. The aim of the study was to evaluate our experience with respect to clinical and pathological staging and long-term results. From 1996 to 2005, 50 patients underwent OLT for HCC including 43 men (86%) and seven women (14%) of median age 57 years (range 37 to 67). All patients fulfilled the Milan criteria. The HCC diagnosis was based on preoperative imaging and alpha-fetoprotein levels;no tumor biopsy was performed. Upon histological examination of the resected specimens, we discovered 6 (12%) incidentalomas and 8 (16%) cases of no HCC. Finally we had 42 "true" HCC. Twenty-six patients (52%) have been downstaged and 10 (20%) upstaged by preoperative imaging;15% were pT1, 45% were pT2, 27% pT3, and 13% pT4a. Twenty-six percent of cases exceeded the Milan criteria. One patient (pT4a) with microvascular invasion died of pulmonary metastases at 14 months after transplantation. No HCC recurrences within the liver have been encountered at a median follow-up of 20 months (range 0 to 80 months). Overall the estimated 1-, 3-, and 5-year survival rates were 83%, 77%, and 72%, respectively. One-, 3-, and 5-year estimated survival rates were 87%, 75%, and 75% for pT1, and pT2, and 75%, 67%, and 67% for pT3 and pT4a, respectively (P =.99). Based on our experience OLT for HCC has long-term results comparable to those without HCC despite the presence of a significant number of cases exceeding the Milan criteria upon pathological staging.

关键词： With staging criteria month Clinical Transplantation of liver Hepatocellular Cancer pT3 Stage Finding Medical Staging Survival Rate pT4a Stage Finding Liver Transplantation tumor biopsy human-centered computing Optical Line Terminal pT2 Stage Finding

来源：评论

学校读者我要写书评

暂无评论

Aromatase inhibitors may be effective in the management of advanced hepatocellular carcinoma

引用

MEDICAL HYPOTHESES 2006年第6期66卷 1257-1257页

作者： Altundag, O Altundag, K Turen, S Gunduz, E Atik, MA Univ Hacettepe Inst Oncol Dept Med Oncol TR-06100 Ankara Turkey Univ Texas Houston Med Sch Med Mem Hermann Hosp Dept Pulm & Crit Care Houston TX 77030 USA Okayama Univ Grad Sch Med & Dent Dept Oral Pathol & Med Okayama 7008530 Japan Baylor Coll Med Dept Neurosurg Houston TX 77030 USA

Hepatocellular carcinoma (HCC) represents the sixth leading cancer and the third most common cause of death from cancer worldwide. There is no firstline option for patients with advanced HCC (vascular invasion, extrahepatic spread, or cancer-related symptoms). Systemic doxorubicin provides partial responses in 10% of cases, without proven survival advantages, and well-known treatment-related complications. Several other treatments, such as immunotherapy, internal radiation, tamoxifen, or anti-androgen agents, have not shown any relevant anti-tumoral effect or survival benefit . Experimentally, estrogens are involved in stimulating hepa-tocyte proliferation in vitro and may act as liver tumor inducers or promoters in vivo. Inefficacy of anti-estrogen tamoxifen however, could be partly attributable to the presence of variant estrogen receptor (ER) forms , or to alternative, non-recep-torial mechanisms potentially involved in growth regulation of both normal and cancer human liver cells by estrogen . By assuming that estrogen plays a role in hepatoma cell growth through non-receptor pathways, we can think of a strategy as reducing estrogen concentration in tumor tissue through aromatase inhibitors that deplete estrogen by inhibiting aromatase, the enzyme that synthesizes estrogen from androgens. One study has investigated the activity and expression of aromatase enzyme in non-tumoral, cirrhotic, and malignant human liver tissues and cells using both chromatographic and reverse transcription) (RT)-PCR analyses. They reported that human HCC tissues showed elevated aromatase activity, with increased estrogen formation rates, as opposed to non-tumoral hepatic tissues . Therefore, aromatase inhibitors may be considered in the management of advanced HCC.

关键词： Aromatase Inhibitors Carcinoma Hepatocellular Estrogens Liver Neoplasms Aromatase Inhibitors Estrogens Cause of Death Aromatase Liver Neoplasms human-centered computing Carcinoma

来源：评论

学校读者我要写书评

暂无评论

Work-centered support systems: A human-centered approach to intelligent system design

引用

IEEE INTELLIGENT SYSTEMS 2005年第2期20卷 73-81页

作者： Scott, R Roth, EM Deutsch, SE Malchiodi, E Kazmierczak, TE Eggleston, RG Kuper, SR Whitaker, RD BBN Technol Intelligent Distributed Comp Dept Eden Prairie MN 55347 USA Roth Cognit Eng Brookline MA 02445 USA BBN Technol Human Ctr Syst Grp Cambridge MA 02138 USA BBN Syst & Technol Global Air Mobil Adv Technol Res Program Ofallon IL 62269 USA USAF Res Lab HECS Wright Patterson AFB OH 45433 USA USAF Res Lab HECS Wright Patterson AFB OH 45433 USA Northrop Grumman Informat Technol Fairborn OH 45324 USA

The work-centered support system approach to human-centered computing focuses on analyzing and supporting the multiple facets of work. The WCSS for global weather management developed to support weather forecasting and monitoring in an airlift service organization, exemplifies this approach. A hallmark of human-centered computing (HCC) is its focus on domain practitioners and their field of practice. human-centered design depends on a deep analysis of a field\'s cognitive and collaborative demands and how people work individually, in groups, and in organizations to meet those demands. The objective is to leverage what we know about human cognitive and collaborative processes to create systems that optimize the affordances (direct perception of meanings) and effectivities (knowledge-driven actions) for humans. The WCSS paradigm offers an approach for incorporating software agent technology in a manner that helps the user keep the head in the work and reduces the possibility that software agent states or actions surprise the user.

关键词： cognition decision support systems geophysics computing human factors software agents user centred design user interfaces weather forecasting airlift service organization global weather management human cognitive process human-centered computing intellig

来源：评论

学校读者我要写书评

暂无评论

human-centered design of a distributed knowledge management system

引用

JOURNAL OF BIOMEDICAL INFORMATICS 2005年第1期38卷 4-17页

作者： Rinkus, S Walji, M Johnson-Throop, KA Malin, JT Turley, JP Smith, JW Zhang, JJ Univ Texas Sch Hlth Informat Sci Houston TX 77030 USA NASA Lyndon B Johnson Space Ctr Houston TX 77058 USA

Many healthcare technology projects fail due to the lack of consideration of human issues, such as workflow, organizational change, and usability, during the design and implementation stages of a project's development process. Even when human issues are considered, the consideration is typically on designing better user interfaces. We argue that human-centered computing goes beyond a better user interface: it should include considerations of users, functions and tasks that are fundamental to human-centered computing. From this perspective, we integrated a previously developed human-centered methodology with a Project Design Lifecycle, and we applied this integration in the design of a complex distributed knowledge management system for the Biomedical Engineer (BME) domain in the Mission Control Center at NASA Johnson Space Center. We analyzed this complex system, identified its problems, generated systems requirements, and provided specifications of a replacement prototype for effective organizational memory and knowledge management. We demonstrated the value provided by our human-centered approach and described the unique properties, structures, and processes discovered using this methodology and how they contributed in the design of the prototype. (C) 2004 Elsevier Inc. All rights reserved.

关键词： human-centered computing organizational memory knowledge management collaborative groupware information systems design ethnographic project lifecycle

来源：评论

学校读者我要写书评

暂无评论

Treatment of hepatocellular carcinoma

引用

BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY 2005年第1期19卷 129-145页

作者： Blum, HE Univ Freiburg Dept Med 2 D-79106 Freiburg Germany

Hepatocellular carcinoma (HCC) is one of the most common malignant tumours worldwide. The major etiologies and risk factors for HCC development are well defined and some of the multiple steps involved in hepatocarcinogeresis have been elucidated in recent years. Despite these scientific advances and the implementation of measures for early HCC detection in patients at risk, patient survival has not improved during the last three decades. This is due in part to the advanced stage of the disease at the time of clinical presentation, in part due to the limited therapeutic options. These fall into four main categories: (1) surgical interventions, incl. tumour resection and liver transplantation, (2) percutaneous interventions, incl. ethanol injection and radiofrequency thermal ablation, (3) transarterial interventions, incl. embolisation and chemoembolisation and (4) drugs as well as gene and immune therapies. These therapeutic strategies have been evaluated in part in randomised controlled clinical trials that are the basis for therapeutic recommendations. While surgery and percutaneous as well as transarterial interventions are effective in patients with limited disease (1-3 lesions, < 5 cm in diameter) and compensated underlying liver disease (cirrhosis Child A), at the time of diagnosis more than 80% patients present with multicentric HCC and advanced liver disease or comorbidities that restrict the therapeutic measures to best supportive care. In order to reduce morbidity and mortality from HCC, therefore, early diagnosis and the development of novel systemic therapies for advanced disease, incl. drugs, gene and immune therapies as well as primary HCC prevention are of paramount importance. Further, secondary HCC prevention after successful therapeutic interventions needs to be improved in order to make an impact on the survival of patients with HCC. New technologies, including gene expression profiling and proteomic analyses, should further elucidate the molecular

关键词： Carcinoma Hepatocellular Liver Neoplasms 癌肝细胞肝肿瘤 intervention therapy Embolization Liver Diseases Controlled Clinical Trials, Randomized human-centered computing Liver Neoplasms Carcinoma

来源：评论

学校读者我要写书评

暂无评论

Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men

引用

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE 2005年第4期97卷 265-272页

作者： Yu, MW Yeh, SH Chen, PJ Liaw, YF Lin, CL Liu, CJ Shih, WL Kao, JH Chen, DS Chen, CJ Natl Taiwan Univ Coll Publ Hlth Grad Inst Epidemiol Taipei 100 Taiwan Natl Taiwan Univ Coll Publ Hlth Dept Publ Hlth Taipei 100 Taiwan Natl Hlth Res Inst Div Mol Genom Med Taipei Taiwan Natl Taiwan Univ Hosp Hepatitis Res Ctr Taipei Taiwan Chang Gung Univ Chang Gung Mem Hosp Liver Res Unit Taoyuan Taiwan Taipei Municipal Jen Ai Hosp Dept Internal Med Div Gastroenterol Taipei Taiwan

Background: Although chronic infection with hepatitis B virus (HBV) has been established as a cause of hepatocellular carcinoma (HCC), the roles of viral load and HBV genotype remain unclear. Methods: From 1988 through 1992, baseline blood samples were collected from 4841 Taiwanese men who were HBV carriers but had not been diagnosed with HCC. We used real-time polymerase chain reaction assays of plasma DNA samples to quantify HBV DNA levels (a measure of viral load) and determine HBV genotypes for 154 case patients who were diagnosed with HCC during 14 years of follow-up and 316 control subjects. Unconditional logistic regression was used to assess odds ratios (ORs) of HCC for HBV-related factors. All statistical tests were two-sided. Results: The risk of HCC increased with increasing HBV viral load (adjusted OR for the highest versus the lowest quintile of HBV DNA copies/mL = 7.26, 95% confidence interval [CI] = 3.54 to 14.89;P-trend < .001). Genotype C HBV was associated with an increased risk of HCC compared with other HBV genotypes (adjusted OR = 5.11, 95% CI = 3.20 to 8.18). Both viral load and genotype were positively associated with HCC within 10-year age categories among subjects aged 30 years old to older than 60 years. Genotype C HBV was associated with increased viral load, and associations of HBV genotype and viral load with HCC risk were additive. The adjusted OR of HCC for those carrying genotype C HBV and with viral load in the highest quintile was 26.49 (95% CI = 10.41 to 67.42) compared with HBV carriers with other HBV genotypes and viral load in the lowest two quintiles. Conclusions: Measurements of HBV viral load and genotype may help to define which male HBV carriers aged 30 years or older are at high risk for HCC.

关键词： Carcinoma Hepatocellular DNA Viral Hepatitis B virus Liver Neoplasms 癌肝细胞病毒肝肿瘤 Prospective Studies Genotype Carcinoma Hepatitis B virus Liver Neoplasms Real-Time Polymerase Chain Reaction Viral Load human-centered computing DNA

来源：评论

学校读者我要写书评

暂无评论

Microvascular tumor embolism: Independent prognostic factor after liver transplantation in hepatocellular carcinoma

引用

TRANSPLANTATION PROCEEDINGS 2005年第2期37卷 1251-1253页

作者： Lee, HH Joh, J Park, JH Lee, KW Heo, JS Choi, SH Kim, SJ Lee, SK Sungkyunkwan Univ Sch Med Samsung Med Ctr Dept Surg Seoul 135710 South Korea

Microscopic tumor cell dissemination may be a more important factor in the recurrence of hepatocellular carcinoma (HCC) after liver transplantation, probably because of posttransplant immnosuppression. The presence of microvascular tumor embolism was undetermined as a factor for HCC recurrence after orthotopic liver transplantation (OLT). This study evaluated whether microvascular tumor embolism affects recurrence-free survival and correlates with other clinicopathologic factors after OLT among patients with HCC. From September 1996 to June 2003,72 OLTs for HCC were enrolled in this study. Median follow-up was 22.8 months. Among 41 patients without microvascular tumor embolism, 1-year, 2-year, and 5-year recurrence-free survival rates were all 97.6%, while these rates were 77.3%, 68.2%, and 59.7%, respectively, for 31 patients (43.1%) with microvascular tumor embolism (P = .0006). The 5-year recurrence-free survival rate showed significant differences for a pT2 tumor (P = .0073), for maximal tumor size < 3 cm (P = .0328), for >= 5 cm solitary tumor (P = .0095), and for the presence of a tumor capsule (P = .0012), within the Milan criteria (P = .0376). At multivariate analysis, significant independent predictors for HCC recurrence were microvascular tumor embolism and histopathologic grade. In conclusion, microvascular tumor embolism is an independent predictor of HCC recurrence after liver transplantation. Although OLT is a safe and effective treatment for HCC within the Milan criteria, the presence of microvascular tumor embolism at pathologic examination can predict its recurrence. In these cases, the feasibility of immunosuppressive therapy or adjuvant chemotherapy must be considered to prevent tumor recurrence.

关键词： Neoplasms Recurrence Embolism Transplantation of liver 肿瘤复发栓塞 Embolism Relapse human-centered computing Neoplasms Optical Line Terminal tumor embolism Liver Transplantation

来源：评论

学校读者我要写书评

暂无评论

Clevudine therapy with vaccine inhibits progression of chronic hepatitis and delays onset of hepatocellular carcinoma in chronic woodchuck hepatitis virus infection

引用

ANTIVIRAL THERAPY 2004年第6期9卷 H4-H5页

作者： Korba, B Cote, P Menne, S Toshkov, I Tennant, BC Gerin, JL Georgetown Univ Med Ctr Div Mol Virol & Immunol Rockville MD USA Cornell Univ New York State Coll Vet Med Dept Clin Sci Ithaca NY 14853 USA

We examined a rational approach to therapy of chronic hepatitis B virus (HBV) infection that utilized the reduction of viral load combined with appropriately timed immune modulation/stimulation. In a placebo-controlled study, chronic woodchuck hepatitis virus (WHV) carrier woodchucks received clevudine (L-FMAU), previously shown to have especially potent and sustained antiviral activity in woodchucks, for 32 weeks followed by WHV surface antigen (WHsAg) alum-adjuvanted vaccine at 32, 36, 40 and 48 weeks. Clevudine induced significant reductions in viraemia, surface antigenaemia, hepatic WHV nucleic acids, and hepatic core and surface antigens. Viral replication markers remained markedly suppressed in 75% of the clevudine-treated woodchucks following drug withdrawal, but remained at high levels in the vaccine monotherapy and placebo groups. Combination drug and vaccine therapy had benefits based on sustained reduction of viraemia, antigenaemia, and hepatic WHV DNA and RNA; inhibition of progression of chronic hepatitis; reduced frequency of chronic liver injury; and delayed onset of hepatocellular carcinoma (HCC). Combination therapy contributed to prevention of HCC in up to 38% of treated carriers, although the growth rate of established HCC was not affected. This study demonstrates enhanced benefits of combination chemo-immunotherapy against viral load and disease progression in chronic hepadnaviral infection, and provides a platform for further development of such treatment regimens.

关键词： Hepatitis B Vaccines Hepatitis B Virus Woodchuck Hepatitis B Chronic 肝炎疫苗乙型肝炎病毒旱獭肝炎慢性 progressions Hepatitis B virus Surface Antigens Vaccines Vaccine Therapy Hepatitis B Vaccines Hepatocellular Cancer liver injury Clevudine Marmota monax Viral Load Hepatitis B Chronic Hepatitis Woodchuck Hepatitis B Virus human-centered computing

来源：评论

学校读者我要写书评

暂无评论

Enhanced anti-rotavirus action of human cystatin C by site-specific glycosylation in yeast

引用

BIOCONJUGATE CHEMISTRY 2004年第6期15卷 1289-1296页

作者： Nakamura, S Hata, J Kawamukai, M Matsuda, H Ogawa, M Nakamura, K Jing, H Kitts, DD Nakai, S Shimane Univ Dept Life & Environm Sci Shimane Shimane 6908504 Japan Shimane Univ Dept Life Sci & Biotechnol Shimane Shimane 6908504 Japan Univ British Columbia Vancouver BC V6T 1Z4 Canada

The cDNA encoding human cystatin C (HCC) was subjected to site-specific substitution of alanine for serine at the position 37, to obtain the Asn(35)-Lys(36)-Ser(37) sequence that is a signal for asparagine-linked (N-linked) glycosylation of protein in eukaryotes, and was transformed into Pichia pastoris X33. As a result, 1.2 mg/L oligomannosyl HCC with a carbohydrate chain of Man(10)GlcNAc(2) was produced by the Pichia transformant. The oligomannosyl HCC was more stable at the low ionic strength condition of 50 mM potassium phosphate buffer, pH 7.0, than the wild-type. In addition, the oligomannosylation substantially improved the molecular stability of cystatin against an aspartic proteinase, cathepsin D, in which the susceptibility decreased to less than 50% of nonglycosylated one. The anti-rotavirus activity of HCC was substantially enhanced by the site-directed glycosylation using the yeast expression system. A MA-104 cell line was used as a host cell for human rotavirus type-2 Wa strain in this study, to which both the wild-type and oligomannosyl. HCCs did not show cytotoxicity at a concentration of 100,mug/mL. More than 80% viability of the host cell infected with 1.0 x 10(5) PFU/mL of rotavirus was conserved under the condition coexisting with 75 mug/mL of the oligomannosyl HCC, which was 15.2% higher than that of wild-type HCC. Thus, the in vitro antirotavirus assay indicated that the supplement of a proper amount of the oligomannosyl HCC could be used as an anti-rotavirus agent.

关键词： Host Cell Rotavirus Yeast Alanine Molecular stability human-centered computing site-specific Cystatins Cystatin C Glycosylation

来源：评论

学校读者我要写书评

暂无评论

Multimodality tumor control and living donor transplantation for unresectable hepatocellular carcinoma

引用

TRANSPLANTATION PROCEEDINGS 2004年第8期36卷 2287-2288页

作者： Chui, AKK Rao, ARN Island, ER Chan, HLY Leung, TWT Lau, WY Chinese Univ Hong Kong Dept Surg Prince Wales Hosp Shatin Hong Kong Peoples R China Chinese Univ Hong Kong Dept Med & Therapeut Prince Wales Hosp Shatin Hong Kong Peoples R China Chinese Univ Hong Kong Dept Oncol Prince Wales Hosp Shatin Hong Kong Peoples R China

Liver transplantation (LT) is an acceptable mode of -treatment for selected patients with unresectable hepatocellular carcinoma (HCC). However, due to the scarcity of cadaveric donor organs, it is considered desirable for patients to opt for living donor liver transplantation (LDLT) or, for those not being transplanted soon, to have some form of tumor control therapy. Such an approach in our program is analyzed and reported. At our institution, 42 LTs were performed between October 1999 and April 2003. Of these, 18 recipients (15 men, 3 women) had 27 HCC. The average number and size of HCC was 1.59 (1 to 4) and 2.31 (0.2 to 6.5) cm, respectively. Thirteen (72%) patients were transplanted primarily for the HCC, whereas five (28%) others were incidental HCC cases. Seven patients (5 LRLT, 2 cadaveric LT) were transplanted soon after listing, and thus did not require tumor control therapy. Six patients waited for 11 (6 to 19) months before LT. Three patients underwent microwave coagulation therapy, and one had additional alcohol injections. One patient received the novel PIAF (cisplatin, interferon, adriamycin, and 5-FU) chemotherapy regimen followed by selective internal irradiation (SIR) treatment. One patient received conformal radiation therapy and another received SIR treatment before LT. Besides 2 postoperative deaths, the remaining 16 patients have been well, with a mean follow-up of 20.4 (3.6 to 41.2) months. In conclusion, for patients with unresectable HCC, in areas with poor cadaveric donor rate, living donation should be the first option. If a suitable live donor is not available, aggressive multimodality therapy is recommended while waiting for cadaveric LT.

关键词： Lymphotoxin livin g unresectable control 淋巴毒素 Level Trigger Organ Donors Combined Modality Therapy Conformal Radiotherapy Lymphotoxin-alpha BIRC7 protein, human human-centered computing Living Donors Patients

来源：评论

学校读者我要写书评

暂无评论

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案：

请选择收藏分类：

通借通还

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：